

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 August 2024 (08.08.2024)



(10) International Publication Number
WO 2024/160722 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61P 25/08 (2006.01)
A61K 31/55 (2006.01) C07D 471/14 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/052061

(22) International Filing Date:

29 January 2024 (29.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23154379.4 01 February 2023 (01.02.2023) EP

(71) Applicant: UCB BIOPHARMA SRL [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: BURSENS, Pierre; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). KEYAERTS, Jean; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). LEDECQ, Marie Adolphe C.; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). MANTEAU, Baptiste; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). PROVINS, Laurent; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE). SWINNEN, Dominique Louis L.; c/o IPD, UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE).

(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Biopharma SRL, 60, Allée de la Recherche, 1070 Brussels (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: TRICYCLIC AZEPINONE DERIVATIVES AS SYSTEM XC INHIBITORS



(57) Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is useful for the treatment of diseases and/or disorders in which System Xc- plays a role.

WO 2024/160722 A1